TD Waterhouse Canada Inc. cut its stake in eBay Inc. (NASDAQ:EBAY – Free Report) by 24.0% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 24,079 shares of the e-commerce company’s stock after selling 7,589 shares during the quarter. TD Waterhouse Canada Inc.’s holdings in eBay were worth $2,109,000 at the end of the most recent reporting period. Get eBay alerts: A number of other large investors also recently bought and sold sha ...

Principal Financial Group Inc. grew its stake in shares of Live Nation Entertainment, Inc. (NYSE:LYV – Free Report) by 22.1% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 9,725,776 shares of the company’s stock after purchasing an additional 1,763,511 shares during the period. Live Nation Entertainment comprises about 0.8% of Principal Financial Group Inc.’s holdings, making the stock its 21st biggest holding. Princi ...

Independent Advisor Alliance lifted its holdings in shares of Truist Financial Corporation (NYSE:TFC – Free Report) by 9.7% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 329,093 shares of the insurance provider’s stock after buying an additional 29,191 shares during the quarter. Independent Advisor Alliance’s holdings in Truist Financial were worth $15,046,000 at the end of the most recent quarter. Get Truist Fin ...

Access Investment Management LLC reduced its stake in Integra LifeSciences Holdings Corporation (NASDAQ:IART – Free Report) by 14.6% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 372,450 shares of the life sciences company’s stock after selling 63,420 shares during the period. Integra LifeSciences accounts for 1.4% of Access Investment Management LLC’s holdings, making the stock its 27th biggest holding. ...

Federated Hermes Inc. decreased its position in Cisco Systems, Inc. (NASDAQ:CSCO – Free Report) by 18.8% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 255,477 shares of the network equipment provider’s stock after selling 59,116 shares during the quarter. Federated Hermes Inc.’s holdings in Cisco Systems were worth $17,480,000 at the end of the most recent reporting period. Get Cisco Systems alerts: A number of othe ...

Atle Fund Management AB decreased its holdings in Amgen Inc. (NASDAQ:AMGN – Free Report) by 42.2% in the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 13,806 shares of the medical research company’s stock after selling 10,088 shares during the period. Amgen makes up about 1.5% of Atle Fund Management AB’s holdings, making the stock its 26th biggest holding. Atle Fund Management AB’s holdings in Amgen were worth $3,896,000 at the end of the most recent ...

Core Insights - AstraZeneca is set to list on the New York Stock Exchange, aiming to strengthen its investment presence in the U.S., its largest market [1][10] - The company is making significant investments in China, including a $15 billion commitment through 2030, to enhance manufacturing and R&D capabilities [4][10] - AstraZeneca's strategy reflects a broader trend in the pharma industry, where companies are increasingly looking to China for innovation as patents on blockbuster drugs expire [2][3] Investment and Partnerships - AstraZeneca's investment in China will cover the entire value chain from drug discovery to manufacturing, highlighting its commitment to Chinese innovation [5] - The company has partnered with Hong Kong-listed CSPC Pharmaceuticals to bolster its obesity portfolio, involving an upfront payment of $1.2 billion and potential additional payments of $17.3 billion based on milestones [6][7] - This partnership is part of a growing trend of licensing deals between Big Pharma and Chinese biotechs, with 57 such deals reported in 2025 [14] Market Dynamics - The U.S. market presents pricing challenges that are pressuring Big Pharma, making the Chinese market increasingly important for revenue and research [2][3][10] - AstraZeneca's commitment to China is underscored by its recent actions, despite facing regulatory scrutiny in the past [12][13] - The Chinese biopharma sector is evolving rapidly, with a focus on next-generation therapeutics and efficient clinical trial processes, positioning it as a potential leader in biotechnology [15][16]

Industry Overview - The leisure industry is characterized by fluctuations in performance based on economic cycles, as consumer spending on discretionary items varies with job security [1] - Despite economic downturns, long-term investors may find opportunities in leisure stocks [2] Royal Caribbean - Royal Caribbean operates under multiple brands, targeting different demographics: families, premium segments, and ultra-luxury markets [2] - The company generates most of its revenue from passenger ticket sales, with onboard revenue contributing about one-third of total revenue [3] - Royal Caribbean reported a strong fourth-quarter performance with a 13.2% year-over-year revenue growth to $4.3 billion, and two-thirds of its capacity already booked for the current year [4] - The company plans to launch four new ships by 2028 to meet strong demand [4] - Royal Caribbean's stock gained 23.3% over the past year, outperforming the S&P 500 by approximately 10 percentage points, and its price-to-earnings (P/E) ratio decreased from 22 to 19 [9] Six Flags - Six Flags merged with Cedar Fair in July 2024, becoming the largest regional theme park operator in North America with 26 amusement parks, 15 water parks, and nine resorts [5] - Despite the larger size, Six Flags faced operational challenges, with Q3 attendance increasing by only 1% and spending per person declining by 4%, leading to a 2.3% year-over-year revenue drop to $1.3 billion [6] - Management's strategy focuses on enhancing guest experience, cutting costs, managing capital expenditures efficiently, and selling non-core assets to drive higher attendance and spending [7] - Six Flags' stock lost 60.5% over the past year, contrasting with the S&P 500's 13.4% gain, indicating significant operational challenges [8]

Company Overview - Harmony Biosciences is a U.S.-based biopharmaceutical company focused on therapies for rare neurological diseases, with WAKIX being a notable product for narcolepsy [5] - The company reported a total revenue of $825.94 million and a net income of $185.68 million for the trailing twelve months (TTM) [4] - The company has 268 employees and experienced a 1-year price change of -5.92% as of January 31, 2026 [4] Recent Executive Transactions - Sandip Kapadia, the Chief Financial Officer, sold 3,746 shares on January 26, 2026, for approximately $139,171 [1][2] - Following this transaction, Kapadia's direct holdings decreased to 24,521 shares from over 127,000 shares in March 2023 [8] - The transaction value was based on a weighted average purchase price of $37.15, with a post-transaction value of $916,105 based on the market close of $37.36 [2] Financial Performance and Outlook - Harmony Biosciences expects to achieve over $1 billion in revenue from WAKIX by the end of 2026, supported by an exclusive license for the medication [9] - The company has other medications in advanced development stages, projected to sustain operations into 2040 [10] - A 10% revenue increase is anticipated for 2025, indicating strong financial results and a positive outlook for investors [10] Investor Implications - Despite the recent sale by Kapadia, Harmony Biosciences' financials remain strong, particularly highlighted by a robust Q3 2025 net income, the highest since Q3 2022 [7] - The recent sale size of 3,746 shares is significantly below Kapadia's median sale size of 13,494 shares, suggesting a potential for further material sales [8]

Core Insights - Artificial intelligence (AI) is identified as the greatest investment opportunity of the current era, with a strong emphasis on the urgency to invest now [1][13] - The energy demands of AI technologies are significant, with data centers consuming as much energy as small cities, leading to concerns about power grid capacity and rising electricity prices [2][3] Investment Opportunity - A specific company is highlighted as a critical player in the AI energy sector, owning essential energy infrastructure assets that are poised to benefit from the increasing energy demands of AI [3][7] - This company is not a chipmaker or cloud platform but is positioned as a "toll booth" operator in the AI energy boom, collecting fees from energy exports and benefiting from the onshoring trend driven by tariffs [5][6] Financial Position - The company is noted for being debt-free and holding a significant cash reserve, amounting to nearly one-third of its market capitalization, which positions it favorably compared to other energy firms burdened by debt [8][10] - It also has a substantial equity stake in another AI-related company, providing investors with indirect exposure to multiple growth opportunities without the associated premium costs [9] Market Trends - The article discusses the broader trends of AI, energy, tariffs, and onshoring, indicating that this company is strategically aligned with these developments [6][14] - The influx of talent into the AI sector is expected to drive continuous innovation and advancements, reinforcing the potential for growth in AI investments [12] Future Outlook - The company is positioned at the heart of America's next-generation power strategy, particularly in nuclear energy, which is seen as a clean and reliable power source for the future [7][14] - The potential for significant returns is emphasized, with projections suggesting a possible 100% return within 12 to 24 months for investors who act quickly [15][19]